Divergence of the feeding and thermogenic pathways influenced by NPY in the hypothalamic PVN of the rat.
Neuropeptide Y (NPY) injected into the paraventricular nucleus (PVN) increases feeding and decreases brown adipose tissue (BAT) uncoupling protein (UCP) and lipoprotein lipase (LPL) mRNA. Previously we reported that the feeding and BAT effects induced by NPY in the PVN are blocked by 50 microg naltrexone (NTX) in the rostral nucleus of the solitary tract (rNTS). We sought to determine whether the effect of rNTS NTX on PVN NPY-induced alterations in energy metabolism occurred at lower doses of NTX. Male Sprague-Dawley rats were fitted with cannulas into two sites: PVN and rNTS. Feeding response, BAT UCP, and LPL mRNA were measured after injection of 0, 5, 10, and 25 microg NTX in the rNTS +/- 1 microg NPY in the PVN. One-hour feeding response to PVN NPY was significantly and dose dependently decreased by 10 and 25 microg rNTS NTX (-23 and -31%, respectively). However, rNTS NTX did not block the PVN NPY-induced decrease in BAT UCP or LPL mRNA. BAT beta-actin mRNA (as a measure of overall changes in gene expression) was unchanged among treatment groups. These results indicate a possible divergence in the PVN NPY feeding-stimulatory/BAT-inhibitory pathway, such that PVN NPY feeding effects may be routed through the rNTS whereas BAT effects may be due to alterations at another neural site.
Kotz
C M
CM
Department of Food Science and Nutrition, Minnesota 55417, USA.
Briggs
J E
JE
Grace
M K
MK
Levine
A S
AS
Billington
C J
CJ
D002001:Adipose Tissue, Brown / Q000187:drug effects / Q000502:physiology*; D000818:Animals; D001833:Body Temperature Regulation / Q000187:drug effects / Q000502:physiology*; D002352:Carrier Proteins / Q000096:biosynthesis / Q000235:genetics; D005247:Feeding Behavior / Q000187:drug effects / Q000502:physiology*; D007473:Ion Channels; D008071:Lipoprotein Lipase / Q000096:biosynthesis; D008297:Male; D008565:Membrane Proteins / Q000096:biosynthesis / Q000235:genetics; D008845:Microinjections; D024101:Mitochondrial Proteins; D009271:Naltrexone / Q000008:administration & dosage / Q000494:pharmacology; D009478:Neuropeptide Y / Q000008:administration & dosage / Q000494:pharmacology* / Q000502:physiology; D010286:Paraventricular Hypothalamic Nucleus / Q000187:drug effects / Q000502:physiology*; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D017207:Rats, Sprague-Dawley; D017552:Solitary Nucleus / Q000187:drug effects / Q000502:physiology*; D013997:Time Factors; D014158:Transcription, Genetic / Q000187:drug effects; D000071256:Uncoupling Protein 1
D002352:Carrier Proteins; D007473:Ion Channels; D008565:Membrane Proteins; D024101:Mitochondrial Proteins; D009478:Neuropeptide Y; D012333:RNA, Messenger; D000071256:Uncoupling Protein 1; D009271:Naltrexone; D008071:Lipoprotein Lipase